计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| E610163-5mg |
5mg |
期货 ![]() |
| |
| E610163-25mg |
25mg |
期货 ![]() |
|
| 别名 | 表罗普林 |
|---|---|
| 英文别名 | Epiroprima | GTPL12327 | Epiroprime [INN-French] | 2,4-Diamino-5-(3,5-diethoxy-4-pyrrol-1-ylbenzyl)pyrimidine | BRN 4273487 | Epiroprim | 5-[(3,5-diethoxy-4-pyrrol-1-yl-phenyl)methyl]pyrimidine-2,4-diamine | 5-[(3,5-diethoxy-4-pyrrol-1-ylphenyl)methyl]pyr |
| 规格或纯度 | Moligand™ |
| 英文名称 | epiroprim |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 5-[(3,5-diethoxy-4-pyrrol-1-ylphenyl)methyl]pyrimidine-2,4-diamine |
| INCHI | 1S/C19H23N5O2/c1-3-25-15-10-13(9-14-12-22-19(21)23-18(14)20)11-16(26-4-2)17(15)24-7-5-6-8-24/h5-8,10-12H,3-4,9H2,1-2H3,(H4,20,21,22,23) |
| InChi Key | NMARPFMJVCXSAV-UHFFFAOYSA-N |
| Smiles | CCOc1cc(cc(c1n1cccc1)OCC)Cc1cnc(nc1N)N |
| Isomeric SMILES | CCOC1=CC(=CC(=C1N2C=CC=C2)OCC)CC3=CN=C(N=C3N)N |
| PubChem CID | 68916 |
| 分子量 | 353.400 g/mol |
|---|---|
| XLogP3 | 2.900 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 353.185 Da |
| 单同位素质量Monoisotopic Mass | 353.185 Da |
| 拓扑极表面积Topological Polar Surface Area | 101.000 Ų |
| 重原子数Heavy Atom Count | 26 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 405.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Then RL, Böhni E, Angehrn P, Plozza-Nottebrock H, Stoeckel K. (1982) New analogs of trimethoprim.. Rev Infect Dis, 4 (2): (372-7). [PMID:7051237] |
| 2. Mehlhorn H, Dankert W, Hartman PG, Then RL. (1995) A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models.. Parasitol Res, 81 (4): (296-301). [PMID:7624286] |
| 3. Locher HH, Schlunegger H, Hartman PG, Angehrn P, Then RL. (1996) Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone.. Antimicrob Agents Chemother, 40 (6): (1376-81). [PMID:8726004] |